QT Imaging Holdings Inc (QTI)

QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon WeekJune 29, 2026 9:28 AM
Business Wire Dr. Raluca Dinu Participates in High-Profile Panels and Awards Ceremony Alongside Leading Healthcare Investors and Women’s Health Experts QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company engaged in the research, development and commercialization of innovative body imaging systems, announces that CEO Dr. Raluca Dinu presented the Shiftmaker Award to Martina Navratilova at the Sports Shiftmaker Awards ceremony last weekend and is participating in a series of thought-provoking women’s health panels during Wimbledon week in London. The panels and ceremony are hosted by The Shift, a mission-driven, intergenerational women's media platform backed by Harvard University, Gloria Steinem, and other prominent leaders, showcasing the stories of women shaping business, culture, and society. “The inspiring conversations taking place this week reflect a growing recognition that women’s health has entered a new era,” said Dr. Dinu. “Patients, clinicians, researchers, entrepreneurs, and investors are aligned around the need for personalized, patient-centered healthcare solutions. As innovation continues to advance, the focus must remain on ensuring these technologies are safe, can meaningfully improve patient experiences, expand access to care, and provide women with the information they need to make informed healthcare decisions. “Martina’s story embodies so many of the themes driving progress in women's health today,” added Dr. Dinu. "As one of the most accomplished athletes in history and a breast cancer survivor, her powerful advocacy highlights the importance of empowering women with information, options, and access to innovative healthcare solutions. It was an honor to share the stage with her and other leaders who are shaping the future of women's health." Dr. Dinu joined global leaders from healthcare, investment, academia, and advocacy to discuss the future of breast health and women’s healthcare innovation. The discussions brought together influential voices focused on advancing women’s health through innovation, investment, patient advocacy, and improved access to care. On June 27, QT Imaging served as the presenting partner for the Shiftmaker Award honoring Navratilova, whose record 59 Grand Slam titles and decades of leadership in women's sports have inspired generations of women worldwide. Following diagnoses for breast and throat cancer, Navratilova has become a prominent advocate for breast health awareness, screening and early detection. Navratilova was recognized with the Shiftmaker Award for her extraordinary achievements in sport and her ongoing advocacy for women's health, resilience and empowerment. Following the award ceremony on June 27 tennis legend and two-time cancer survivor Martina Navratilova, biotech investor Kriti Lall of Perceptive Advisors, and award-winning journalist Sophia Li joined Dr. Dinu to present, “The Paradigm Shift: Redefining the Standard of Care in Women’s Health.” The discussion brought together the patient, innovation, and investment perspectives to explore how advances in breast health, early detection, and personalized care are transforming outcomes for women worldwide. Today, Dr. Dinu will participate in “The Era of the Execution Shift for Women’s Health: Scaling Science and Access in Women’s Health,” a panel focused on leading innovation in women's health, with a focus on breast cancer. The panel features biotech investor Susan Wang of T. Rowe Price, Caroline Jefferies of the Center for Research in Women’s Health, and Jaya Rosenmeir, Global Head of Clinical at Novartis. It is being moderated by a journalist from ELLE UK. Throughout the forums, panelists discussed how the convergence of patient advocacy, technological innovation, scientific research, and investment capital is driving meaningful progress in women’s health. Discussions also highlighted the increasing focus on breast health, breast density awareness, personalized screening approaches, and the importance of improving the patient experience throughout the continuum of care. QT Imaging’s participation underscores its commitment to advancing breast health through innovative imaging technologies that provide clinicians and patients with additional quantitative information and support a more comfortable patient experience. The Company’s involvement in the forums also aligns with its broader mission to help shape the future of breast health through technologies that support more personalized, patient-centered approaches to care. About QT Imaging QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems that use low-frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn. Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the repeatability and reproducibility metrics for quantitative biomarkers generated by the QT Imaging Breast Acoustic CT Scanner, and what that means for its commercialization, advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260629028187/en/ Investors
CORE IR
Tirth Patel

$QTI: Positive Saudi News of Clearance

QT Imaging Receives Saudi Arabia FDA Regulatory Clearance

Share






Allows for Commercial Deployment of the Company’s Radiation-Free Breast Imaging Technology Under Distribution Agreement with Gulf Medical Co.

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that its Breast Acoustic CT™ scanner has received official classification and clearance from the Kingdom of Saudi Arabia (KSA) for use as a medical device in that country.

The Saudi Food and Drug Authority (SFDA) approval allows QT Imaging’s Breast Acoustic CT™ scanner to be marketed, sold, and deployed throughout Saudi Arabia, one of the largest healthcare markets in the Middle East. The approval marks a significant milestone in the Company’s international expansion strategy and further strengthens its growing commercial presence across the Gulf region.

In August 2025, QT Imaging entered into an exclusive distribution agreement with Gulf Medical Co., a leading provider of healthcare technologies in Saudi Arabia. With SFDA approval now secured, Gulf Medical is positioned to begin commercial activities and engage healthcare institutions throughout the Kingdom.

Saudi Arabia continues to invest heavily in healthcare modernization and women's health initiatives as part of Vision 2030 and its Health Sector Transformation Program, which aims to improve healthcare access, quality, preventive care, and digital health infrastructure across the Kingdom.(1) Breast cancer remains the most commonly diagnosed cancer among women in the Kingdom,(2) creating an increasing demand for advanced, patient friendly imaging technologies that improve access to screening and diagnostic services.

“Receiving SFDA approval is a major achievement for QT Imaging and an important step in our global commercialization strategy,” said Satrajit Misra, Chief Commercial Officer of QT Imaging. “Saudi Arabia represents one of the most attractive healthcare markets in the region. This approval enables us to begin commercial deployment with our partner Gulf Medical and expands access to our radiation free, compression free 3D breast imaging technology for women throughout the Kingdom.”

“The approval further demonstrates QT Imaging’s ability to successfully navigate international regulatory pathways and positions the Company for continued growth across the Middle East and other global markets,” added Misra.

With regulatory clearances now secured in both Saudi Arabia and the United Arab Emirates, QT Imaging has established a commercial foundation in the two largest healthcare markets in the Gulf region.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the QT Imaging Breast Acoustic CT Scanner, including its commercialization in the UAE and Saudi Arabia, manufacturing (including large scale) and further development, advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

(1) Saudi Vision 2030, Health Sector Transformation Program https://www.vision2030.gov.sa/en/explore/programs/health-sector-transformation-program. Accessed June 2026.

(2) Global Cancer Observatory (GLOBOCAN 2022), International Agency for Research on Cancer (IARC), World Health Organization. Saudi Arabia Fact Sheet: https://gco.iarc.who.int


Contacts
Investors
Alliance Advisors IR
Jody Cain
Jcain@allianceadvisors.com
310-691-7107

Media
Alliance Advisors IR
Fatema Bhabrawala
fbhabrawala@allianceadvisors.com
647-620-5002


GO $QTI

QT Imaging Holdings Announces Closing of $10 Million Underwritten Public OfferingMay 18, 2026 4:15 PM
Business Wire QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (Nasdaq: QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today the closing of its previously announced underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of approximately $10 million. Participants in this offering included current investors in QT Imaging as well as new investors. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as sole book-running manager and Northland Capital Markets acted as co-manager for the offering. The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-294705), which was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on April 3, 2026 and the related registration statement filed under Rule 462(b) of the Securities Act of 1933, as amended, which became automatically effective upon filing. A final prospectus supplement was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus may also be obtained by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn. Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the underwritten public offering, the use of proceeds from such offering, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging’s expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging’s assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260518201981/en/ Investors
Alliance Advisors IR
Bruce Voss

QT Imaging Holdings Announces Pricing of $10 Million Underwritten Public OfferingMay 15, 2026 8:30 AM
Business Wire QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (Nasdaq: QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today the pricing of an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of $10 million. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager and Northland Capital Markets is acting as co-manager for the offering. “This capital raise marks an important milestone for our company and reflects strong investor confidence in our strategy, execution, and long-term market opportunity,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “This financing along with the extension of the maturity date of our senior secured term loan by two years provide the Company with additional flexibility to focus on our commercial, clinical, and strategic growth initiatives.” Each share of common stock is being sold to the public at a public offering price of $5.00 per share and each pre-funded warrant is being sold to the public at the public offering price of each share of common stock less the $0.0001 per share nominal exercise price for each pre-funded warrant. Gross proceeds to the Company from this offering are expected to be approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock, and may be exercised at any time until exercised in full. QT Imaging intends to use the net proceeds from the offering for working capital and for general corporate purposes. This offering is expected to close on or about May 18, 2026, subject to the satisfaction of customary closing conditions. The securities described in this press release are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-294705), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on April 3, 2026, and the related registration statement filed under Rule 462(b) of the Securities Act of 1933, as amended, which became automatically effective upon filing. The offering will be made only by means of a written prospectus that forms part of the effective registration statement. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn. Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the proposed public offering, the use of proceeds from such offering, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging’s expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging’s assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515630388/en/ Investors
Alliance Advisors IR
Bruce Voss

QT Imaging Reports First Quarter 2026 Revenue of $6.5 MillionMay 13, 2026 8:15 AM
Business Wire Revenue of $6.5 Million, Up 133% Year-Over-Year with 13 Scanners Shipped Two Year Extension of the Maturity Date of the Senior Secured Term Loan to March 31, 2029 Secured a Category III CPT Code Specific to QT Imaging, Paving the Way to U.S. Reimbursement Conference Call Begins Today at 4:30 p.m. Eastern Time QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three months ended March 31, 2026 and provided a business update. “We continued to execute during the first quarter, making meaningful progress across commercialization, regulatory execution, and clinical validation,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “During the quarter, we shipped 13 QT Breast Acoustic CT™ systems, in line with our commercial distribution commitments, secured a dedicated Category III CPT code for our technology that becomes effective as of January 2027, and received FDA 510(k) clearance for enhancements that improve visualization of posterior breast tissue. “Recently, the maturity date of our senior secured term loan with our lender was extended by two years from March 31, 2027 to March 31, 2029. This extension provides the Company with additional financial flexibility as we continue executing on our commercial, clinical, and strategic growth initiatives. “Importantly, we also expanded internationally with regulatory clearance in the United Arab Emirates, supporting a previously established multiyear commercial agreement in the region. At the same time, we advanced our technology platform through the launch of the QT Imaging-Olea Viewer and released a meaningful software improvement focused on reflection image quality, workflow, and quantitative analysis. “Our clinical strategy continues to gain momentum through investigator studies at leading institutions that demonstrate strong concordance between QTscan and MRI. We believe QTscan is uniquely positioned as a radiation-free, compression-free, true 3D breast-imaging platform capable of providing quantitative information meant to improve clinical decision making, particularly for women with dense breasts. We remain focused on disciplined execution as we expand adoption of the platform globally,” she added. First Quarter and Recent Business Highlights Shipped 13 Breast Acoustic CT scanners in the first quarter of 2026 through our Amended NXC Distribution Agreement. Generated additional clinical evidence supporting agreement of the QTscan with MRI through investigator studies. A prospective pilot study at the Mayo Clinic evaluated QTscan as a supplemental screening tool in high-risk women and demonstrated absolute agreement between QT Imaging and MRI, suggesting comparable effectiveness of QT Imaging and MRI in identifying positive findings. Secured American Medical Association (AMA) approval of a new Category III CPT code, X579T, for 3D quantitative transmission volumetric ultrasound tomography of the breast. This code recognizes the distinct clinical service enabled by QTI's Breast Acoustic CT system’s radiation-free, compression-free, 3D breast-imaging platform, and becomes effective January 1, 2027. Received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of QTI's Breast Acoustic CT scanner, which is designed to enhance visualization and expand imaging coverage of the posterior breast tissue, a region that is challenging to capture. Received official classification and clearance from the United Arab Emirates (UAE) Emirates Drug Establishment for use of QTI’s Breast Acoustic CT scanners and the QT Imaging’s Cloud SaaS Platform subscription. QT Imaging has an exclusive distribution agreement for the UAE with Al Naghi Medical Co., a leading regional distributor of medical devices in the Gulf region. The agreement provides for committed minimum order quantities (MOQs) of seven scanners in 2026, increasing to 16 scanners in 2027 and 20 scanners in 2028, for a total minimum of 43 scanners representing revenue of more than $24 million. Launched the QT Imaging-Olea Viewer, which provides a unified platform for viewing multiple breast imaging modalities, enabling clinicians to efficiently correlate findings across multi-imaging sources and monitor patients longitudinally to streamline workflow. The viewer is designed to enhance clinical efficiency and support more informed patient management. Released software update version 4.5.0, a next-generation image reconstruction that improves spatial resolution in reflection imaging, resulting in more accurate image representation while maintaining efficient processing time. Uplisted to The Nasdaq Capital Market after having met all listing requirements, including financial, corporate governance, and regulatory criteria. Named renowned breast cancer researcher Dr. Mary W. Yamashita as Medical Advisor to provide strategic advisory and development support across several key areas, including optimizing clinical integration and user experience, and ensuring the Company’s technologies meets and exceeds the expectations of clinicians and patients. Welcomed Dr. Barry Roseman, a breast surgical oncologist with more than 25 years of experience treating breast cancer and breast disease, as Senior Medical Advisor. Dr. Roseman’s engagement includes clinical implementation of the QT Imaging technology in his diagnostic and screening center to support physician training, workflow integration, patient access, and ongoing collection of real-world clinical, operational, financial, patient, and provider experiences. Subsequent to the close of the quarter, the Company amended the Lynrock Lake Credit Agreement, extending the maturity date of the senior secured term loan by two years to March 31, 2029, and increasing the interest rate to 12.0% per annum from 10.0% previously. First Quarter Financial Results Revenue for the first quarter of 2026 was $6.5 million, an increase of 133% from $2.8 million for the first quarter of 2025. The increase was primarily attributable to the shipment of 13 Breast Acoustic CT scanners in the 2026 quarter compared with six scanners in the prior-year period. Gross margin for the first quarter of 2026 was 41% compared with 65% for the first quarter of 2025. The higher gross margin in the first quarter of 2025 was primarily due to the sale of two majorly depreciated scanners, hence with a lower cost basis. Total operating expenses for the first quarter of 2026 were $5.0 million compared with $2.9 million for the same period of 2025. The increase was primarily attributable to employee compensation and professional and outside service costs. Total interest and other expense, net for the first quarter of 2026 was $1.1 million compared with $10.1 million for the first quarter of 2025. The decrease was primarily due to $8.8 million in nonrecurring charges recorded in the prior-year period, including noncash expense related to the issuance of the Lynrock Lake Term Loan and the extinguishment and modification charges associated with the Yorkville and Cable Car Notes. The decrease was partially offset by higher interest expense driven by accrued interest and debt discount amortization on the Lynrock Lake Term Loan. Net loss for the first quarter of 2026 of $3.4 million, or $0.25 per share, compared with a net loss of $11.1 million, or $1.21 per share, for the first quarter of 2025. Non-GAAP adjusted EBITDA* for the first quarter of 2026 of $(1.9) million compared with $(0.9) million for the first quarter of 2025. Net cash used in operating activities during the first quarter of 2026 was $3.7 million compared with $3.5 million during the first quarter of 2025. Cash, restricted cash, and cash equivalents were $7.0 million as of March 31, 2026 compared with $10.5 million as of December 31, 2025. 2026 Revenue Guidance The Company reaffirms guidance for 2026 revenue to be approximately $39 million, reflecting scanner shipments in the U.S. and world-wide, and initial revenue from the QT Imaging Cloud Platform. These expectations are in accordance with the MOQs per its Amended Distribution Agreement with its U.S. strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, as well as its new distribution partners in the Gulf region, Gulf Medical and Al Naghi Medical. Conference Call and Webcast QT Imaging management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those who choose not to pre-register can access the live conference call by dialing 866-777-2509 from within the U.S. and 412-317-5413 from outside the U.S. and requesting the QT Imaging call. A live and archived webcast of the conference call will be available on the IR Calendar section of the Company website. Non-GAAP Financial Measures Some of the financial information and data contained in this press release, such as EBITDA and Adjusted EBITDA, have not been prepared in accordance with GAAP. To supplement our unaudited condensed consolidated financial statements, which are prepared and presented in accordance with GAAP in our press release, we also report certain non-GAAP financial measures. A “non-GAAP financial measure” refers to a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes (or includes) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in such company’s financial statements. Non-GAAP financial measures should not be considered in isolation or as a substitute for the relevant GAAP measures and should be read in conjunction with information presented on a GAAP basis. Because not all companies use identical calculations, our presentation of non-GAAP measures may not be comparable to other similarly titled measures of other companies. The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP and should not be considered measures of QT Imaging's liquidity. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, many of the adjustments to our GAAP financial measures reflect the exclusion of certain items, as defined in our non-GAAP definitions below, which are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, even where similarly titled, limiting their usefulness for comparison purposes and therefore should not be used to compare QT Imaging’s performance to that of other companies. We endeavor to compensate for the limitation of the non-GAAP financial measures presented by also providing the most directly comparable GAAP measures and descriptions of the reconciling items and adjustments to derive the non-GAAP financial measures. We believe these non-GAAP financial measures provide investors and analysts with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key measures used by management to operate and analyze our business over different periods of time. EBITDA is defined as loss before interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for stock-based compensation, net change in fair value of the derivative, earnout and warrant liabilities, transaction expenses, warrant modification expense, loss on debt extinguishment, debt issuance expense and other income (expense), net. Similar excluded expenses may be incurred in future periods when calculating these measures. QT Imaging believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. QT Imaging believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing QT Imaging’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s consolidated financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which expense and income items are excluded or included in determining these non-GAAP financial measures. Management uses EBITDA and Adjusted EBITDA as a non-GAAP performance measure that is defined in the accompanying tables and is reconciled to net loss, the most directly comparable GAAP measure, in the tables below. We present reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures in the tables below. About QT Imaging QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com. Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding any express or implied statements or guidance regarding current or future financial performance and position, including shipments to the Gulf region, QTI's Breast Acoustic CT scanner, including its commercialization, manufacturing (including large scale) and further development, the evolution of QT Imaging into a scalable imaging platform combining proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools to address the growing need for precision in breast health, the QTI Cloud Platform and SaaS pricing model, performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy QTI’s Breast Acoustic CT Scanner; the impact on military actions in the Gulf region on the Company’s ability to ship products to that region.; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring-to-market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans, or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements. Summary of Results For the Three Months Ended March 31, 2026 and 2025 (Unaudited)     Three Months Ended $ thousands (except per share amounts) 2026   2025 Revenue $ 6,530     $ 2,798   Cost of revenue   3,858       986   Gross profit   2,672       1,812   Operating expenses:       Research and development   1,724       852   Selling, general and administrative   3,297       2,002   Total operating expenses   5,021       2,854   Loss from operations   (2,349 )     (1,042 ) Interest and other expense, net:       Interest expense, net   (930 )     (691 ) Other expense, net   (4 )     (8,749 ) Change in fair value of warrant liability   (173 )     (705 ) Change in fair value of derivative liability   —       101   Change in fair value of earnout liability   50       (50 ) Total interest and other expense, net   (1,057 )     (10,094 ) Net loss   (3,406 )     (11,136 ) Net loss attributable to common stockholders $ (3,406 )   $ (11,136 )         Net loss per share - basic and diluted (1) $ (0.25 )   $ (1.21 )         Weighted-average shares outstanding (1)   13,798       9,172   (1)   Share and per share amounts for the three months ended March 31, 2025 differ from those published in prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split. Specifically, the number of shares of common stock outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 3:1, such that each three shares of common stock were combined and reconstituted into one share of common stock effective October 23, 2025. EBITDA and Adjusted EBITDA For the Three Months Ended March 31, 2026 and 2025 (Unaudited)     Three Months Ended $ thousands 2026   2025 Net loss $ (3,406 )   $ (11,136 ) Interest expense, net   930       691   Depreciation and amortization   20       38   EBITDA   (2,456 )     (10,407 ) Other expense, net   4       (15 ) Debt issuance expense (1)   —       6,640   Debt modification and extinguishment expenses (2)   —       2,124   Change in fair value of warrant liability (3)   173       705   Change in fair value of derivative liability( 4)   —       (101 ) Change in fair value of earnout liability (5)   (50 )     50   Stock-based compensation   381       101   Adjusted EBITDA $ (1,948 )   $ (903 ) (1)   Upon the issuance of the Lynrock Lake Term Loan, which closed on February 26, 2025, the Company recorded a loss of $6.6 million, including debt issuance costs of $0.2 million, in other expense, net for the three months ended March 31, 2025.       (2)   The Company recorded debt modification expense of $0.1 million primarily related to its modification of the Cable Car Note on January 9, 2025 and debt extinguishment expense of $2.0 million related to the extinguishment of the Yorkville Note and Cable Car Note on February 26, 2025 in other expense, net for the three months ended March 31, 2025.       (3)   The increase in fair value of warrant liability during the three months ended March 31, 2026 relates to the increase in the market value of the public warrants outstanding as of March 31, 2026. The increase in fair value of warrant liability during the three months ended March 31, 2025 relates to the liability classified private placement warrants, the Lynrock Lake Warrant, and Yorkville Warrant, which were primarily driven by an increase in the Company's stock price from the date of issuance of the Lynrock Lake Warrant and Yorkville Warrant and as of March 31, 2025. The Lynrock Lake Warrant and Yorkville Warrant were modified and subsequently reclassified to equity on June 11, 2025.       (4)   The decrease in fair value of derivative liability during the three months ended March 31, 2025 related to the Yorkville Pre-paid Advance, which contained features that were bifurcated as freestanding financial instruments and initially valued on March 4, 2024 upon consummation of the Merger. The derivative liability was subsequently revalued as of February 26, 2025, prior to the extinguishment of the Yorkville Note.       (5)   The earnout liability relates to the contingent consideration for the Merger Earnout Consideration Shares pursuant to the Business Combination Agreement dated December 8, 2022, as amended in September 2023. The earnout liability was initially valued using the Monte Carlo Simulation method on March 4, 2024 and subsequently revalued using the same method as of March 31, 2026 and 2025. Consolidated Balance Sheets As of March 31, 2026 and December 31, 2025 (Unaudited)   $ in thousands March 31,
2026   December 31,
2025 Assets       Current assets:       Cash and cash equivalents $ 6,900     $ 10,412   Restricted cash and cash equivalents   50       50   Accounts receivable, net   6,353       5,781   Inventory   6,826       5,027   Prepaid expenses and other current assets   1,068       821   Total current assets   21,197       22,091           Property and equipment, net   315       318   Operating lease right-of-use assets, net   477       573   Other assets   39       39   Total assets $ 22,028     $ 23,021           Liabilities and Stockholders' Equity       Current liabilities:       Accounts payable $ 2,927     $ 3,580   Accrued expenses and other current liabilities   5,131       3,825   Current maturities of long-term debt   —       9   Operating lease liabilities, current   467       454   Total current liabilities   8,525       7,868   Long-term debt   1,360       683   Related party notes payable   3,895       3,895   Operating lease liabilities   82       203   Warrant liability   276       103   Earnout liability   2,160       2,210   Other liabilities   1,931       1,614   Total liabilities   18,229       16,576           Stockholders’ equity:       Common stock   1       1   Additional paid-in capital   60,228       59,468   Accumulated deficit   (56,430 )     (53,024 ) Total stockholders’ equity   3,799       6,445   Total liabilities and stockholders’ equity $ 22,028     $ 23,021   Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2026 and 2025 (Unaudited)     Three Months Ended $ in thousands 2026   2025 Cash flows from operating activities:       Net loss $ (3,406 )   $ (11,136 ) Adjustments to reconcile net loss to net cash used in operating activities:       Depreciation and amortization   20       38   Stock-based compensation   381       101   Loss on issuance of the Lynrock Lake Term Loan   —       6,640   Debt modification expense   —       90   Loss on debt extinguishment   —       2,034   Non-cash interest   677       477   Non-cash operating lease   (12 )     (9 ) Change in fair value of warrant liability   173       705   Change in fair value of derivative liability   —       (101 ) Change in fair value of earnout liability   (50 )     50   Changes in operating assets and liabilities:       Accounts receivable   (572 )     (2,715 ) Inventory   (1,799 )     268   Prepaid expenses and other current assets   (247 )     (635 ) Accounts payable   (495 )     61   Accrued expenses and other current liabilities   468       461   Other liabilities   1,208       135   Net cash used in operating activities   (3,654 )     (3,536 )         Cash flows from investing activities:       Purchases of property and equipment   (17 )     —   Net cash used in investing activities   (17 )     —           Cash flows from financing activities:       Proceeds from sale of common stock and warrants   155       —   Proceeds from long-term debt, net of issuance costs   —       10,000   Repayment of long-term debt   (9 )     (4,648 ) Cash paid for stock issuance costs   (232 )     —   Proceeds from stock option exercises   245     —   Net cash provided by financing activities   159       5,352   Net increase in cash and cash equivalents and restricted cash and cash equivalents   (3,512 )     1,816   Cash and cash equivalents and restricted cash and cash equivalents, beginning balance   10,462       1,192   Cash and cash equivalents and restricted cash and cash equivalents, ending balance $ 6,950     $ 3,008     View source version on businesswire.com: https://www.businesswire.com/news/home/20260513639808/en/ Investors
Alliance Advisors IR
Bruce Voss

QT Imaging Releases Its Next Generation Breast Imaging Reconstruction SoftwareApril 1, 2026 8:30 AM
Business Wire
– New generation reconstruction software improves image quality and performance across challenging breast imaging cases –


QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced its latest image reconstruction software update release, version 4.5.0. This next-generation software improves spatial resolution in reflection imaging by implementing optimized, spatially varying deconvolution during reflection image reconstruction, resulting in more accurate image representation while maintaining efficient processing times.


Version 4.5.0 also introduces enhanced reflection images generated through the fusion of speed of sound and reflection data, providing clinicians and researchers with improved visualization and more comprehensive tissue characterization information. These enhancements are designed to improve image interpretation and support comprehensive and reproducible analysis across a wide range of cases.


"The enhanced reflection images represent a meaningful improvement in image quality and usability. Combining reflection with speed of sound information provides additional insight that was not previously available from reflection imaging alone," said Dr. John Tentinger, President and Chief Executive Officer at Innovative Radiology, a radiology center in West Des Moines, Iowa, and a QT Imaging customer.


In addition, the 4.5.0 release includes improved image reconstruction for small breasts and the implementation of more accurate assessment of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and expanding the software’s usability across a broader range of patient anatomies.


“Building on our multimodal imaging approach, we are advancing the development of attenuation as an additional quantitative biomarker, to complement speed of sound and reflection intensity. The integration of attenuation is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support," said Dr. James Wiskin, QT Imaging Fellow.


These advancements reflect QT Imaging’s continued focus on improving image quality, clinical reliability, and workflow efficiency, and represent another important step in the company’s ongoing development of advanced imaging software solutions.


About QT Imaging


QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.


Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the updated reconstruction software, including its capabilities and advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401748847/en/
Investors

Alliance Advisors IR

Jody Cain

Jcain@allianceadvisors.com

310-691-7107


Media

Alliance Advisors IR

Fatema Bhabrawala

fbhabrawala@allianceadvisors.com

647-620-5002


Original: QT Imaging Releases Its Next Generation Breast Imaging Reconstruction Software

$QTI: Upgraded to NASDAQ baby......................


Just like $GOAI did yesterday and ran from $5 to $40 in PreMarket.

This will run to $50 next week !!!!!!!!!


Now at $5.70


GO $QTI

QTIH changed to QTI. Moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

$QTIH: Hit $5.40 !!!!!!!!!!!!!

Nooooooooobodyyyyyyyyyyyyyy here................ Just yo BOY !!!!!!!!!!


GO JAYS !!!!!!!!!!!!!!


GO $QTIH

$QTIH: Huggeeeeeeeee $33Milly Saudi Medical DEAL

https://www.businesswire.com/news/home/20250825493476/en/QT-Imaging-Inks-Exclusive-Distribution-Agreement-with-Gulf-Medical-for-Saudi-Arabia

Let them eat........ while the market snoozes on this one :)

GO $QTIH

$QTIH: Moreeeeee good NEWS... no one gets it.

Except for yo boyyyyyyyyyyyyyyyy............. now $2.22


THE BEST BREAST IMAGING TECHNOLOGY OUT THERE................. BAR NONE !!!!!!!!

https://www.qtimaging.com/


Game CHANGER..... watch them get bought out by Medtronics or some other MEGA
Medical Device maker............... MANIFEST it BABY !!!!

GO $QTIH


**************************************************************************

QT Imaging Bolsters Medical and Clinical Leadership with Senior Appointments to Further Drive Innovation and Clinical Adoption
Elaine luanow, MD, a Boston-based, Board-Certified Breast Radiologist, joins the Company as Chief Medical Officer

Kim Du, an expert in clinical development strategy, clinical operations, and regulatory compliance, is named Senior Director of Clinical Operations

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce the appointments of Elaine Iuanow, MD, as Chief Medical Officer (“CMO”) and Kim Du as Senior Director of Clinical Operations. These additions to the leadership team significantly enhance the Company’s medical and clinical capabilities as QTI expands its clinical studies as well as the development of AI-driven lesion classification and second-read decision support tools alongside the commercialization of its FDA-cleared QTI Breast Acoustic CT™ scanner.

“On behalf of the entire team, I’m thrilled to welcome Elaine and Kim to QT Imaging,” said Dr. Raluca Dinu, CEO of QTI. “They bring deep clinical expertise and leadership that will be critical as we enter our next chapter: expanding our evidence base, driving reimbursement, and transforming QTI into a precision imaging AI company. Their contributions will help us advance not only the clinical adoption of our platform but also a new generation of AI-enhanced diagnostic tools that support improved outcomes, earlier detection, and broader access.”

As CMO, Dr. Iuanow will lead clinical strategy and development, regulatory engagement, and external partnerships with thought leaders and institutions, while supporting QTI’s broader strategic focus of AI-driven precision imaging and diagnostic innovation. A board-certified radiologist with more than two decades of experience in women’s health, breast imaging, and academic medicine, Dr. Iuanow has held clinical positions at Beth Israel Deaconess Medical Center/Harvard Medical School and Brigham and Women's Community Radiology Division. She completed her residency at Tufts Medical Center and a breast imaging fellowship at Faulkner-Sagoff/Brigham and Women’s Hospital.

“From a patient’s perspective, breast imaging should be accurate, comfortable, and stress-free,” said Dr. Iuanow. “QTI’s unique Breast Acoustic CT™ technology combines true 3D anatomical and quantitative imaging with the power of artificial intelligence. It has the potential to become a highly accessible and affordable alternative to MRI—especially for the 50% of U.S. women between 40–74 with dense breast tissue1. I’m honored to join a team committed to fundamentally improving diagnostic confidence and patient experience.”

Dr. Iuanow added: “With our multi-center, evidence-based clinical trial portfolio, QTI will be studied as an alternative to MRI for imaging high-risk women and for breast cancer management in the neoadjuvant setting, as well as a potential platform for future minimally invasive radiologic treatment of breast cancer. I’m especially excited about the development of AI-driven tools that automate findings classification and deliver consistent second-read decision support.”

Ms. Du joins QTI with over fifteen years of medical product development experience. Most recently, she served as Senior Director of Clinical Operations for Avisi Technologies, a clinical-stage ophthalmic device company. Prior to Avisi, she held a variety of clinical research management roles at leading medical device innovators, such as Alcon, Avinger and SentreHEART. Ms. Du earned a Bachelor of Science, Bioengineering and Biomedical Engineering from the University of Washington in 2007.

As Senior Director of Clinical Operations, Ms. Du is responsible for the strategic leadership and execution of the Company’s clinical trials across all phases of development. She oversees trial planning, site and vendor management, Good Clinical Practice (GCP) compliance, data integrity, and team performance to help ensure the successful execution of studies that support additional regulatory approvals, product adoption, and commercialization.

Sources

1 Breast Density on a Mammogram, Susan G. Komen

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, clinical studies, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20250708534534r1&sid=acqr8&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708534534/en/

For media inquiries, please contact:

Stephen Kilmer
Head of Investor Relations
Stephen.Kilmer@qtimaging.com
Direct: (646) 274-3580

Source: QT Imaging Holdings, Inc.

© Copyright Business Wire 2025

QTIH DELISTED TO OTC PLAY READY TO RUMBLE